On 25 July 2024, Galderma announced that results from its Phase III trials on nemolizumab, published in The Lancet, demonstrate statistically and clinically significant improvements in inflammation and itch in moderate to severe atopic dermatitis. The studies evaluated the efficacy and safety of nemolizumab in combination with background topical corticosteroids (TCS), with or without topical calcineurin inhibitors (TCI), versus placebo in combination with TCS, with or without TCI.
On 7 May 2024, Galderma announced that nemolizumab had been accepted for review, under the Access Consortium Framework, in Australia, Singapore, Switzerland and the UK for prurigo nodularis and moderate to severe atopic dermatitis. Regulatory filings for nemolizumab were accepted by the FDA and EMA in February 2024.